NPHS2 and ganglioneuroma: In summary, our study strongly suggests that NPHS2‐Cre+/− transgenic mice on a C57BL/6J background can be safely used for podocyte‐specific gene inactivation in control conditions and in the anti‐GBM‐GN model.